Breaking News
March 24, 2018 - Kids with severe brain injuries may develop ADHD: study
March 24, 2018 - Researchers explore ways to help older adults taper off and stop using sedatives
March 24, 2018 - Back pain being mismanaged globally
March 24, 2018 - Fingerprint test accurately and noninvasively detects heroin, cocaine users
March 24, 2018 - Leading experts to promote cardiovascular health at EuroPrevent 2018
March 24, 2018 - A Role for Rituximab in Lupus?
March 24, 2018 - New osteoarthritis genes discovered
March 24, 2018 - Maternal intake of DHA supplement linked to higher fat-free body mass in children
March 24, 2018 - Royal College of Pathologists‘ bulletin provides summary of Tissue Handling Workshop
March 24, 2018 - Maternal alcohol use early in pregnancy may be risk factor for infant abdominal malformation
March 24, 2018 - Savara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung Infection
March 24, 2018 - Accelerated WBI Should be the Norm for Most Breast Cancers
March 24, 2018 - Experts seek to standardize treatments for childhood rheumatic diseases
March 24, 2018 - Foil-based measuring chip rapidly detects Legionella
March 24, 2018 - Bariatric surgery linked to positive outcomes in very obese adolescents with type 2 diabetes
March 24, 2018 - Are there risks from secondhand marijuana smoke? Early science says yes.
March 24, 2018 - New University of Bath project seeks to make injections safer
March 24, 2018 - Higher-dose RT does not improve survival but reduces recurrence risk for prostate cancer patients
March 24, 2018 - Researchers examine link between knee pain and depression in older adults
March 24, 2018 - FDA Alert: BD Vacutainer Blood Collection Tubes by Becton, Dickinson and Company (BD): Class I Recall
March 24, 2018 - Daytime Sleepiness Linked to Amyloid Accumulation Without Dementia
March 24, 2018 - Energy storehouses in the brain may be source of Alzheimer’s, targets of new therapy
March 24, 2018 - Praising people with autism shows promise for producing more exercise
March 24, 2018 - Using harmless red or infrared light to diagnose breast cancer
March 24, 2018 - Clash over abortion hobbles a health bill. Again. Here’s how.
March 23, 2018 - Virtual nature environment could be new way to recover from stress
March 23, 2018 - New study identifies key cellular mechanisms behind vascular aging in mice
March 23, 2018 - Nightmares Common Among U.S. Troops, But Seldom Reported
March 23, 2018 - Another Record Low for Tuberculosis in U.S.
March 23, 2018 - Changes in the eye connected to a decline in memory
March 23, 2018 - Radiologist creates dramatic teaching tool using power of VR
March 23, 2018 - Grilled meat could be raising the risk of hypertension finds study
March 23, 2018 - Mutations found in bassoon gene may help explain cause of rare brain disorder
March 23, 2018 - Childhood Brain Injuries May be Linked to ADHD Years Later
March 23, 2018 - Why treating addiction with medication should be carefully considered
March 23, 2018 - Researchers make key discovery about cellular pathway linked to myriad of diseases
March 23, 2018 - Researchers uncover cause of rare childhood neurodegenerative disease
March 23, 2018 - Measles infection in early childhood could contribute to later COPD
March 23, 2018 - Opioid painkiller is top prescription in 11 states
March 23, 2018 - Sienna Biopharmaceuticals Announces First Patient Dosed In Proof-of-Concept Trial of Topical By Design™ JAK Inhibitor SNA-125 for Atopic Dermatitis
March 23, 2018 - In Teen Girls, Neural Patterns May Drive Emotional Resilience
March 23, 2018 - Gene-based test for urine detects, monitors bladder cancer
March 23, 2018 - BD to introduce new digital solution for IV chemotherapy administration process at EAHP 2018
March 23, 2018 - New computational method helps to identify tumor cell mutations with greater accuracy
March 23, 2018 - Researchers identify potential obesity treatment in freezing hunger-signaling nerve
March 23, 2018 - Wales participates in the 100,000 Genomes Project
March 23, 2018 - 24-Hr Paging Cuts ED Visits for Kids with Endocrine Issues
March 23, 2018 - The brain learns completely differently than we’ve assumed since the 20th century
March 23, 2018 - Less nutritious diet mainly contributes to Type 2 diabetes among U.S.-based South Asians
March 23, 2018 - Stony Brook Medicine expert provides tips for healthy diet to decrease cancer risk
March 23, 2018 - New findings could have revolutionary impact on quality of life of older people
March 23, 2018 - Restoring enzyme may help reverse effects of vascular aging, study shows
March 23, 2018 - Protein profiling reveals new prostate cancer mechanisms
March 23, 2018 - Depression may be linked to increased risk of atrial fibrillation
March 23, 2018 - FDA Takes Aim at Flavored Tobacco
March 23, 2018 - SMART Strategy Lowers Asthma Exacerbation Risk
March 23, 2018 - Cold open water plunge provides instant pain relief
March 23, 2018 - Portable and wearable technology supports future of military medical devices
March 23, 2018 - Patients with vascular malformations have poor health-related quality of life
March 23, 2018 - Researchers develop unique technology to overcome global antibiotic resistance crisis
March 23, 2018 - New DOD grant to support testing of promising therapy for triple-negative breast cancer
March 23, 2018 - Novel vaccine technologies can help better prepare for future infectious disease threats
March 23, 2018 - OncoBreak: Colonoscopy TV; Coverage for Genomic Testing; Care for Caregivers
March 23, 2018 - For some surgeries, nerve blocks mean better outcomes, fewer opioids
March 23, 2018 - Maternal obesity and androgen excess induce sex-specific anxiety in offspring, study suggests
March 23, 2018 - The tale of Theranos and the mysterious fire alarm
March 23, 2018 - USC researchers create algorithm to optimize substance abuse intervention groups
March 23, 2018 - Impulsivity may be associated with greater weight loss during treatment in obese children
March 23, 2018 - CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
March 23, 2018 - Senate Panel Addresses Native Americans’ Opioid Troubles
March 23, 2018 - Brain connections in schizophrenia
March 23, 2018 - Mental health assessment in health checks can help detect psychologically vulnerable people
March 23, 2018 - New test for urothelial cancers offers less invasive, more accurate detection
March 23, 2018 - Groundbreaking 100,000 Genomes Project achieves important milestone to transform NHS care
March 23, 2018 - Mice getting a new lease of life with anti-aging pills
March 23, 2018 - Obesity kills taste buds and dulls taste sensation finds study
March 23, 2018 - Medical students get less formal education in radiation oncology, study finds
March 23, 2018 - Researchers find investigational compound to treat triple negative breast cancer after brain metastasis
March 23, 2018 - Researchers develop wearable system to monitor electrical activity in the stomach over 24 hours
March 23, 2018 - A Different Opioid Crisis | Medpage Today
MediciNova Announces Positive Top-Line Results from the Clinical Trial of MN-166 (ibudilast) in ALS

MediciNova Announces Positive Top-Line Results from the Clinical Trial of MN-166 (ibudilast) in ALS

image_pdfDownload PDFimage_print

LA JOLLA, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive top-line results from MediciNova’s clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS). Data analysis was conducted on the 51 subjects without non-invasive ventilation in the ITT (Intent To Treat) population. The trial achieved the primary endpoint of safety and tolerability, and also demonstrated efficacy trends in favor of MN-166 (ibudilast).

MN-166 (ibudilast) demonstrated a favorable safety and tolerability profile. All subjects in the study received 100 mg of riluzole per day. There were 7 serious adverse events (SAEs) reported during the study but none of the SAEs were related to the study drug. All treatment-related adverse events (TRAEs) were mild to moderate in intensity and no severe or life-threatening TRAEs were reported. The most frequently reported TRAEs were nausea, anorexia, and loss of appetite, which were expected and are common side effects of both riluzole treatment and MN-166 (ibudilast) treatment.

There was a higher rate of responders on the ALSFRS-R total score in the MN-166 (ibudilast) group compared to the placebo group. The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) total score measures the functional activity of an ALS subject. ALS subjects decline on the ALSFRS-R total score over time as the disease progresses and their symptoms worsen. A responder was defined as a subject that improved on the ALSFRS-R total score, had no change on the score, or the score declined by 1 point. If a subject’s ALSFRS-R total score declined by 2 points or more, they were considered a non-responder. During the six-month, double-blind portion of the study, 29.4% of subjects in the MN-166 (ibudilast) group were responders compared to 17.6% of subjects in the placebo group. For the subjects who were treated with placebo during the six-month, double-blind portion of the study and then switched to MN-166 (ibudilast) treatment during the six-month open-label extension, 35.3% of subjects were responders when taking MN-166 (ibudilast).

There was a higher rate of responders on the ALSAQ-5 score in the MN-166 (ibudilast) group compared to the placebo group. The Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-5) score measures the physical mobility, activities of daily living and independence, eating and drinking, communication, and emotional functioning. A responder was defined as a subject that improved on the ALSAQ-5 score or had no change on the score. If a subject’s ALSAQ-5 score worsened, they were considered a non-responder. During the six-month, double-blind portion of the study, 50.0% of subjects in the MN-166 (ibudilast) group were responders compared to 23.5% of subjects in the placebo group. For the subjects who were treated with placebo during the six-month, double-blind portion of the study and then switched to MN-166 (ibudilast) treatment during the six-month open-label extension, 29.4% of subjects were responders when taking MN-166 (ibudilast). Overall, 43.1% of subjects treated with MN-166 (ibudilast) for six months were responders, and this was significantly higher than the 23.5% of placebo-treated subjects who were responders (p=0.046).

This was the first study of MN-166 (ibudilast) in ALS and the study provides the necessary clinical data for powering assumptions for the next study of MN-166 (ibudilast) in ALS.

The top-line results will be presented as an oral presentation at the 28th International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) at the Westin Boston Waterfront in Boston, MA, USA on Friday, December 8, 2017 at 4:00 P.M., Eastern Time. The presentation entitled “Ibudilast: Bi-modal therapy with riluzole in early and advanced ALS patients” will be given by principal investigator Dr. Benjamin Rix Brooks, Director, Carolinas Neuromuscular/ALS-MDA Center at Carolinas HealthCare System Neurosciences Institute.

Dr. Benjamin Rix Brooks, principal investigator, commented, “The results of this study are very encouraging and indicate that MN-166 has the potential to stop disease progression and improve functional activity in some ALS patients. This is an impressive effect that has not been observed in studies of other drugs for ALS. We are excited to participate in the further development of MN-166 for this devastating disease.”

Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, “We are very pleased with the top-line data as this study achieved both goals we set out to achieve: (1) MN-166 was safe and well tolerated in ALS, and (2) MN-166 demonstrated efficacy trends that warrants further investigation in a larger ALS study. We look forward to the results from the second study of MN-166 in ALS, which is ongoing at Massachusetts General Hospital and is using a higher dose of 100 mg of MN-166 per day.”

About the ALS Trial

MediciNova, in collaboration with Dr. Benjamin Rix Brooks, Director, Carolinas Neuromuscular/ALS-MDA Center at Carolinas HealthCare System Neurosciences Institute, evaluated 60 mg of MN-166 (ibudilast) per day in early and advanced stage ALS patients. All subjects in the study received 100 mg of riluzole per day. This trial was a randomized, double-blind, placebo-controlled study which included a six-month treatment period followed by a six-month open-label extension. The primary endpoint was safety and tolerability and the study also evaluated several efficacy endpoints including functional activity (ALSFRS-R).

About ALS

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. The nerves lose the ability to trigger specific muscles, which causes the muscles to become weak. As a result, ALS affects voluntary movement and patients in the later stages of the disease may become completely paralyzed. Life expectancy of an ALS patient is usually 2-5 years. According to the ALS Association, there are approximately 20,000 ALS patients in the U.S. and approximately 6,000 people in the U.S. are diagnosed with ALS each year.

About MN-166 (ibudilast)

MN-166 (ibudilast) has been marketed in Japan and Korea since 1989 to treat post-stroke complications and bronchial asthma. MediciNova is developing MN-166 for progressive multiple sclerosis (MS) and other neurological conditions such as ALS and substance abuse/addiction. MN-166 (ibudilast) is a first-in-class, orally bioavailable, small molecule phosphodiesterase (PDE) -4 and -10 inhibitor and a macrophage migration inhibitory factor (MIF) inhibitor that suppresses pro-inflammatory cytokines and promotes neurotrophic factors. It attenuates activated glia cells, which play a major role in certain neurological conditions. Ibudilast’s anti-neuroinflammatory and neuroprotective actions have been demonstrated in preclinical and clinical study results and provide the rationale for its therapeutic utility in neurodegenerative diseases (e.g., progressive MS and ALS), substance abuse/addiction and chronic neuropathic pain. MediciNova has a portfolio of patents which cover the use of MN-166 (ibudilast) to treat various diseases including progressive MS, ALS, and drug addiction.

About MediciNova

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. market. MediciNova’s current strategy is to focus on MN-166 (ibudilast) for neurological disorders such as progressive MS, ALS and substance dependence (e.g., alcohol use disorder, methamphetamine dependence, opioid dependence) and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). MediciNova’s pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbations of asthma and MN-029 (denibulin) for solid tumor cancers. MediciNova is engaged in strategic partnering and other potential funding discussions to support further development of its programs. For more information on MediciNova, Inc., please visit

Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-221, MN-001, and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “estimates,” “projects,” “can,” “could,” “may,” “will,” “would,” “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-221, MN-001, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova’s operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova’s collaborations with third parties, the availability of funds to complete product development plans and MediciNova’s ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova’s filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2016 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

Source: MediciNova, Inc.

Posted: December 2017

Tagged with:

About author

Related Articles